Cytyc — Citigroup Investor Conference (May 2007)
36 slides from Cytyc's conference presentation, May 29, 2007
Slide 1: Citigroup Investor Conference
CitiGroup Investor Conference Jack W. Cumming Chairman & CEO Glenn Muir Exec VP & CFO May 23, 2007 Filed by Hologic, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Cytyc Corporation Commissio
Slide 2: Disclaimer Regarding Forward-Looking Statements
Disclaimer Regarding Forward-Looking Statements Information set forth in this communication contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits of Hologic’s
Slide 3: Disclaimer Regarding Forward-Looking Statements (continued)
Disclaimer Regarding Forward-Looking Statements (continued) growth; use and protection of intellectual property; dependence on customers' capital spending policies and government funding policies, including third-party reimbursement; realization of potential future savings from new productivity init
Slide 4: Important Information for Investors and Stockholders
Hologic and Cytyc will file a joint proxy statement/prospectus with the SEC in connection with the proposed merger. HOLOGIC AND CYTYC URGE INVESTORS AND STOCKHOLDERS TO READ THE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE AND ANY OTHER RELEVANT DOCUMENTS FILED BY EITHER PARTY WITH THE
Slide 5: Participants in the Solicitation
Participants in the Solicitation Hologic, and certain of its directors and executive officers, may be deemed participants in the solicitation of proxies from the stockholders of Hologic in connection with the merger. The names of Hologic’s directors and executive officers and a description of their
Slide 6: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the non-GAAP financial measures "adjusted EPS" and “EBITDA”. Adjusted EPS excludes the write-off and amortization of acquisition-related intang
Slide 7: A History of Innovation
A History of Innovation Delphi HOLOGIC Goes Public Acquisition of Trex Medical Including LORAD Launched in U.S. Introduced 3D DEXA Acquisition of R2, Suros and AEG Fan-Beam Technology Founding of HOLOGIC Announced Agreement with Cytyc Introduced Tomosynthesis at RSNA Launched Discovery Acquisition o
Slide 8: Hologic Overview
Hologic Overview Women’s health imaging market leader – Strong/profitable core businesses (mammography/densitometry) – Technology and market share leader (# 1 market share in U.S.) Major opportunity in digital mammography – Large, emerging digital market – Digital technology evolving as standard of
Slide 9: Financial Overview
Financial Overview Record Q2 FY07 revenues of $180 million Record Q2 FY07 pre-tax income of $33.9 million Backlog of $216 million as of quarter-end 3/31/07 Q2 FY07 Performance (March 31st) up 79% over Q2 FY06 up 94% over Q2 FY06 up 41% or $63 million over 3/25/06 Strong Growth
Slide 10: LORAD Mammography/Breast Care
$129 $189 $336 Up 99% Over 1 st Half FY06 78% of Revenues LORAD Mammography/Breast Care Recognized technology leader worldwide Market share leader in the U.S. >50% share in analog/digital Unsurpassed image quality – High transmission cellular grid - patented Largest installed base – 13,000 system $2
Slide 11: Direct Conversion Technology Optimal
Direct Conversion Technology Optimal > 72% of Mammography/Breast Care Product Revenue LORAD Selenia FFDM First U.S. system delivered in March 2003 555 Selenias sold in FY06 228 Selenias sold in Q1 FY07 282 Selenias sold in Q2 FY07 Backlog increased to 533 systems at end of Q2 FY07 up 132% over FY05
Slide 12: Number of Selenias Sold
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Selenia Highlights: 555 sold in FY06 510 sold in first half of FY07 Approximately 38% of estimated 3,900+ worldwide FFDM installed market Accelerating Interest *For Fiscal Years Ended September th Number of Selenia’s Sold * Full Field Digital Mam
Slide 13: MQSA U.S. Scorecard
MQSA U.S. Scorecard* (Mammography Quality Standards Act of 1992) Total Certified Facilities 8,800 Total Accredited Units 13,447 Certified Facilities with FFDM Units 1,795 20.4% Accredited FFDM Units 2,637 19.6% Total U.S. Annual = 34.7 Million Mammography Procedures Hologic U.S. Installed Base (at M
Slide 14: Tomosynthesis
Tomosynthesis Technology Roadmap Lower recall rates Improved detection – False positives – costly – False negatives – deadly Incorporated in screening Digital Tomosynthesis Tomosynthesis Offers the Potential for:
Slide 15: Vacuum Assist Breast Biopsy Systems
Vacuum Assist Breast Biopsy Systems Leading technology for VABB Leverages U.S. sales and distribution channels FY06 sales of approximately $38 million – High gross margin product exceeding 65% – Over 70% of revenues derived from recurring disposable sales – Growth rate of over 50% in each of next tw
Slide 16: Suros ATEC System Positioned to Maximize Conversion to VABB
Ultrasound Stereotactic MRI Suros ATEC ® System Is Ideally Positioned to Maximize Conversion to VABB Procedures Suros’ Innovative Technologies with New and Improved Screening Modalities Will Drive Conversion 1.8 Million Breast Biopsy Procedures Annually in the U.S. 500,000 600,000 700,000
Slide 17: Celero
Celero ™ - The First - Vacuum-Assisted, Spring Loaded Core Biopsy Device for Breast Ultrasound Celero breast biopsy device with CeleroMark™ biopsy marker system and introducer Celero Advantages - Faster and less traumatic for the patient - Provides better access to hard-to-reach lesions - Better cor
Slide 18: Creating a Global Leader in Women's Healthcare
Creating a Global Leader in Women’s Healthcare Continuing a legacy of leading technology, innovation and rapid growth
Slide 19: Creating a Global Leader in Women's Healthcare
Creating a Global Leader in Women’s Healthcare
Slide 20: Strategic Rationale / Combined Strengths
Strategic Rationale Combined Strengths Strategic Rational Creating a Global Leader in Women’s Healthcare Expanded product portfolio Comprehensive sales coverage Ability to leverage OB/GYN channel Significant cross-selling synergies with breast surgeons/radiation oncologists/mammographers Enhanced in
Slide 21: Best-in-Class Solutions in Women's Healthcare
Selenia Breast Cancer Screening MammoSite Radiation Therapy ThinPrep Pap Test & Imaging System Cervical Cancer Screening NovaSure Endometrial Ablation Adiana Contraception FullTerm - Adeza Preterm Labor Best-in-Class Solutions in Women’s Healthcare Comprehensive Women’s Healthcare Platform Discovery
Slide 22: Solutions for Major Women's Healthcare Issues
Endometriosis Permanent Contraception Preterm Labor Osteoporosis Menorrhagia Cervical Cancer Breast Cancer Solutions for Major Women’s Healthcare Issues Helica Adiana Fetal Fibronectin Discovery Sahara NovaSure ThinPrep Selenia MultiCare Suros ATEC MammoSite Combined Offering Unpenetrated High Mediu
Slide 23: {.HOLOGIC
{.HOLOGIC Thal
Slide 24: Slide 24
Slide 25: Leveraging the OB/GYN Channel
Screening Test Diagnostic Test Treatment Specialist Therapeutic Improved Outcomes OB/Gyn Our Mission Leveraging the OB/GYN Channel Best Technology Selenia, ThinPrep, Adeza, Discovery Minimally Invasive Most Specific Suros, MultiCare, Selenia, Discovery Channel Access to Gatekeeper 230 OB/Gyn sales r
Slide 26: In-Depth Channel Coverage
58 Breast Surgery & Radiation Oncology 77 Radiology & Imaging Center 110 Gynecology Surgery Over 425 U.S. Sales Representatives OB/Gyn & Primary Care Physicians Clinical Lab Multiple call points to women’s healthcare providers Access to – 30,000 OB/Gyn’s – 40,000 Radiologists – 10,000 Hospitals & Im
Slide 27: New Product Pipeline
New Product Pipeline Interventional products to address extraction of benign fibroid adenomas – 350-500k procedures per year Percutaneous removal of confirmed breast cancer – 75-100k procedures per year Radiation oncology for treatment of breast cancer
Slide 28: Long-Term Strategic Goals
Drive market growth through a combination of advanced technology and comprehensive sales channel coverage #1 market position in major areas of women’s healthcare Continue 20%+ revenue and earnings growth Develop additional best-in-class products that provide earlier and better detection, improved di
Slide 29: Transaction Overview
Transaction Overview Permanent financing anticipated to be combination of pre-payable term loan and equity-linked securities Financing: Hologic, Inc. (NASDAQ: HOLX), continue Cytyc name Name of NewCo: Third Quarter of CY2007 Timing to Close: Shareholders of both companies, customary closing conditio
Slide 30: Financial Rationale
Multiple platforms to enhance top and bottom line growth Increased scale through diversification of revenue and strong margin profile Enhanced cash flow; LQA EBITDA of ~$436M Revenue and cost synergy opportunities Estimated more than $0.10 accretive to adjusted EPS within the first full year after c
Slide 31: Diversified and Balanced Revenue Mix
Gynecology Interventional 16% Gynecology Diagnostics 33% NovaSure 30% Pap 56% Diversified and Balanced Revenue Mix Breast Health 40% Osteoporosis & Other 11% Combined Company LQA Revenue = $1.44B ~ 40% Capital Equipment ~ 60% Consumables Other 1% MammoSite 5% Adeza 8% Other 12% Breast Biopsy 9% Oste
Slide 32: Combined Financial Strength
Combined Financial Strength 46% Gross Margin $161M EBITDA $724M Revenue LQA Hologic 75% Gross Margin $275M EBITDA $720M Revenue LQA Cytyc 60% Gross Margin $436M EBITDA $1.44B Revenue LQA Combined Company
Slide 33: Significant Synergy Opportunity
$25-$30M projected cost savings within two years Align assets to maximize efficiencies Leverage combined purchasing power Consolidate administrative activities Greater than $75M revenue projected opportunities within three years Cross-selling to OB/Gyn/breast surgeon/mammographer/radiation oncologis
Slide 34: FY2008 Guidance and Long Term Outlook
FY2008 Guidance and Long Term Outlook 2008 Guidance Revenue: In excess of $1.70B Adjusted EPS : $2.35-$2.40 / share Gross margin: 65% Long-Term Outlook Revenue Growth: 20% Adjusted EPS Growth: 20%+ Adjusted EPS excludes the write-off and amortization of acquisition-related intangible assets, and rel
Slide 35: Creating a Global Leader in Women's Healthcare
Creating a Global Leader in Women’s Healthcare Comprehensive Women’s Healthcare Product Portfolio – Complementary best-in-class technologies Expanded Commercial Capabilities – Expansive U.S. sales channel coverage – Enhanced presence in key international markets – Platform for entry into new markets
Slide 36: Creating A Global Leader In Women's Healthcare
Creating A Global Leader In Women’s Healthcare